245 related articles for article (PubMed ID: 30278072)
21. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
22. DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.
Tripathi V; Popescu NC; Zimonjic DB
Oncogene; 2014 Feb; 33(6):724-33. PubMed ID: 23376848
[TBL] [Abstract][Full Text] [Related]
23. Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma.
Yang X; Hu F; Liu JA; Yu S; Cheung MPL; Liu X; Ng IO; Guan XY; Wong KKW; Sharma R; Lung HL; Jiao Y; Lee LTO; Cheung M
Oncogene; 2020 May; 39(20):4061-4076. PubMed ID: 32214200
[TBL] [Abstract][Full Text] [Related]
24. H2O2 inhibits proliferation and mediates suppression of migration via DLC1/RhoA signaling in cancer cells.
Ma L; Zhu WZ; Liu TT; Fu HL; Liu ZJ; Yang BW; Song TY; Li GR
Asian Pac J Cancer Prev; 2015; 16(4):1637-42. PubMed ID: 25743845
[TBL] [Abstract][Full Text] [Related]
25. Expression of an estrogen-regulated variant transcript of the peroxisomal branched chain fatty acid oxidase ACOX2 in breast carcinomas.
Bjørklund SS; Kristensen VN; Seiler M; Kumar S; Alnæs GI; Ming Y; Kerrigan J; Naume B; Sachidanandam R; Bhanot G; Børresen-Dale AL; Ganesan S
BMC Cancer; 2015 Jul; 15():524. PubMed ID: 26183823
[TBL] [Abstract][Full Text] [Related]
26. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
28. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
29. Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma.
Ko FC; Yeung YS; Wong CM; Chan LK; Poon RT; Ng IO; Yam JW
Liver Int; 2010 Jan; 30(1):139-48. PubMed ID: 19874489
[TBL] [Abstract][Full Text] [Related]
30. MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway.
Wu H; Li J; Guo E; Luo S; Wang G
Cell Physiol Biochem; 2018; 48(2):461-474. PubMed ID: 30016800
[TBL] [Abstract][Full Text] [Related]
31. The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer.
Sabbir MG; Prieditis H; Ravinsky E; Mowat MR
PLoS One; 2012; 7(7):e40302. PubMed ID: 22792269
[TBL] [Abstract][Full Text] [Related]
32. Tumor suppressor gene DLC1: Its modifications, interactive molecules, and potential prospects for clinical cancer application.
Ren G; Li G
Int J Biol Macromol; 2021 Jul; 182():264-275. PubMed ID: 33836193
[TBL] [Abstract][Full Text] [Related]
33. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
34. Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.
Sánchez-Martín D; Otsuka A; Kabashima K; Ha T; Wang D; Qian X; Lowy DR; Tosato G
J Natl Cancer Inst; 2018 Apr; 110(4):390-399. PubMed ID: 29202196
[TBL] [Abstract][Full Text] [Related]
35. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
Yam JW; Ko FC; Chan CY; Jin DY; Ng IO
Cancer Res; 2006 Sep; 66(17):8367-72. PubMed ID: 16951145
[TBL] [Abstract][Full Text] [Related]
36. 17beta-hydroxysteroid dehydrogenase type 5 is negatively correlated to apoptosis inhibitor GRP78 and tumor-secreted protein PGK1, and modulates breast cancer cell viability and proliferation.
Xu D; Aka JA; Wang R; Lin SX
J Steroid Biochem Mol Biol; 2017 Jul; 171():270-280. PubMed ID: 28457968
[TBL] [Abstract][Full Text] [Related]
37. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.
Ravi A; Kaushik S; Ravichandran A; Pan CQ; Low BC
J Biol Chem; 2015 Feb; 290(7):4149-62. PubMed ID: 25525271
[TBL] [Abstract][Full Text] [Related]
39. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells.
Sengupta S; Schiff R; Katzenellenbogen BS
Breast Cancer Res Treat; 2009 Sep; 117(2):243-51. PubMed ID: 18807177
[TBL] [Abstract][Full Text] [Related]
40. Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis.
Ko FC; Chan LK; Tung EK; Lowe SW; Ng IO; Yam JW
Gastroenterology; 2010 Oct; 139(4):1397-407. PubMed ID: 20600027
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
